Evidence mapPaperPMID 41572215Full record

ArticleBMC public health2026

Anthropometric indicators and risk of relapse or second malignant neoplasms in childhood cancer survivors: a scoping review.

Nathalia Rodrigues de Souza, Renata de Souza-Silva, Gabriela Vasconcellos de Barros Vianna, Paula Aballo Nunes Machado, Luciana Grucci Maya Moreira, Camila Belo Tavares Ferreira, Thainá Alves Malhão

Abstract readScoping Review
In one paragraph

Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nathalia Rodrigues de SouzaNational Cancer Institute (INCA), Rua Marquês de Pombal, 125/5° andar, Centro, Rio de Janeiro, RJ, 20230-240, Brazil. uerjnathalia@gmail.com.
Renata de Souza-SilvaBrookdale Community College, Lincroft, NJ, USA.
Gabriela Vasconcellos de Barros ViannaNational Cancer Institute (INCA), Rua Marquês de Pombal, 125/5° andar, Centro, Rio de Janeiro, RJ, 20230-240, Brazil.
Paula Aballo Nunes MachadoNational Cancer Institute (INCA), Rua Marquês de Pombal, 125/5° andar, Centro, Rio de Janeiro, RJ, 20230-240, Brazil.
Luciana Grucci Maya MoreiraNational Cancer Institute (INCA), Rua Marquês de Pombal, 125/5° andar, Centro, Rio de Janeiro, RJ, 20230-240, Brazil.
Camila Belo Tavares FerreiraNational Cancer Institute (INCA), Rua Marquês de Pombal, 125/5° andar, Centro, Rio de Janeiro, RJ, 20230-240, Brazil.
Thainá Alves MalhãoNational Cancer Institute (INCA), Rua Marquês de Pombal, 125/5° andar, Centro, Rio de Janeiro, RJ, 20230-240, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGrowing evidence suggests that diet and nutrition play a critical role in cancer development and progression. However, most research focuses on adult populations, leaving significant knowledge gaps regarding childhood cancer survivors (CCS). Scoping reviews can help identify these gaps and inform clinical decision-making and cancer control strategies.

objectiveThis review initially aimed to identify and map dietary and nutritional risk factors potentially associated with relapse, recurrence, or second malignant neoplasms (SMNs) in CCS. However, during the review process, only studies reporting anthropometric indicators were identified, and evidence was available for two outcomes (relapse and SMNs).

methodsThis scoping review was conducted in accordance with the Joanna Briggs Institute Manual for Scoping Reviews and the PRISMA-ScR guidelines. Studies were eligible if they included: Population – CCS; Concept – dietary and nutritional factors; Context – relapse, recurrence, or SMNs. Cohort and case–control studies were included from PubMed/MEDLINE, Embase, Scopus, Web of Science, and LILACS, without restrictions on language or publication year. Additional studies were identified using AI-based tools and bibliographic alerts. Results were synthesized narratively and thematically mapped. Methodological quality was assessed using the Newcastle–Ottawa Scale.

resultsEight studies (seven cohorts, one case–control), published between 2007 and 2025, were included, covering a total of 39,847 CCS. Acute lymphoblastic leukemia was the most commonly studied cancer type. Four studies examined relapse, three focused on SMNs, and one addressed both outcomes. Follow-up durations ranged from 2.7 to 20.1 years. All studies reported controlling for confounding factors, and only one disclosed financial conflict. Nutritional status was primarily assessed using BMI (six studies); one study also included body composition, and another employed multiple anthropometric indices. Five studies found that excess body weight significantly increased the risk of relapse or SMNs. None of the studies comprehensively evaluated dietary intake or other nutritional dimensions. All studies were classified as being of good quality and at low risk of bias, according to the Newcastle–Ottawa Scale.

conclusionAlthough obesity may be associated with an increased risk of relapse and SMNs in CCS, current evidence is limited, heterogeneous, and does not include dietary and other nutritional factors. Well-designed, longitudinal studies using standardized and comprehensive nutritional assessments are necessary to understand these associations better and support evidence-based survivorship guidelines.

Indexed as

AnthropometryCancer SurvivorsNeoplasm Recurrence, LocalNeoplasms, Second PrimaryChildDietHumansRisk FactorsChildhood cancer survivorsDietary factorsNutritional factorsRecurrenceRelapseSecond malignant neoplasm

Identifiers

PMID41572215
PMCPMC12911064

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.